KZR
NASDAQ · Biotechnology
Kezar Life Sciences Inc
$7.40
-0.02 (-0.27%)
Financial Highlights (FY 2025)
Revenue
16.79M
Net Income
1.29M
Gross Margin
33.7%
Profit Margin
7.7%
Rev Growth
+17.9%
D/E Ratio
0.82
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 33.7% | 33.7% | 33.7% |
| Operating Margin | 8.2% | 9.1% | 8.2% |
| Profit Margin | 7.7% | 7.5% | 7.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.79M | 17.27M | 15.12M |
| Gross Profit | 5.67M | 5.83M | 5.10M |
| Operating Income | 1.38M | 1.57M | 1.24M |
| Net Income | 1.29M | 1.30M | 1.12M |
| Gross Margin | 33.7% | 33.7% | 33.7% |
| Operating Margin | 8.2% | 9.1% | 8.2% |
| Profit Margin | 7.7% | 7.5% | 7.4% |
| Rev Growth | +17.9% | +7.1% | +16.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 15.46M | 15.87M | 20.32M |
| Total Equity | 18.82M | 17.65M | 20.76M |
| D/E Ratio | 0.82 | 0.90 | 0.98 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 2.04M | 2.03M | 1.93M |
| Free Cash Flow | 959.0K | 942.1K | 1.29M |